Hormonal
Roux-en-Y gastric bypass (RYGB) surgery produces distinct circulating metabolite signatures (specifically higher propionate and conjugated bile acids in good responders) that correlate with weight loss response, independent of gut microbiota composition or hunger/satiety hormone levels.
If you are considering or have had gastric bypass surgery, know that 'success' isn't just about how much weight you lose. The surgery changes your body's chemistry (specifically bile acids and gut byproducts like propionate) in ways that might improve your metabolism even if the scale doesn't move as much as expected. This means metabolic health improvements can happen independently of massive weight loss, and tracking these internal markers might be more important than just the number on the scale.
While fecal and circulating metabolite analyses showed higher levels of propionate (p = 0.0001) in good and valerate (p = 0.04) in bad responders, respectively, conjugated primary and secondary bile acids were higher in good responders in the fasted (p = 0.03) and postprandial state... Differences in weight loss did not reflect in metabolic outcome after RYGB.
Why this rating
Observational cohort study with a small sample size (n=23) and long post-operative timeframes (4+ years), limiting causal inference regarding the timing of metabolite changes.
Source
Metabolic Profile and Metabolite Analyses in Extreme Weight Responders to Gastric Bypass Surgery
Charlotte Fries et al. · Metabolites · 2022
DOI 10.3390/metabo12050417
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →